Stepan (NYSE: SCL) CFO gets equity grants, fixes SAR exercise price
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
STEPAN CO Vice President and Chief Financial Officer Ruben Dario Velasquez reported multiple equity-based awards and an administrative correction. On March 2, 2026, he received 8,586 Stock Appreciation Rights tied to common stock with a conversion/exercise price of $50.06 and expiration on March 3, 2036. He was also granted 2,996 performance shares, which vest upon certification that performance goals for the period ending December 31, 2028 are achieved, and 5,993 restricted stock units that vest ratably over three years beginning on the grant date. In a separate award dated February 27, 2026, he acquired 35.601 shares of common stock at $52.51 per share. This Form 4/A amends a prior filing solely to correct the Stock Appreciation Right conversion/exercise price to $50.06 from $17.47; no other terms of the reported transactions are changed.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Velasquez Ruben Dario
Role
VP and Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 5,993 | $0.00 | -- |
| Grant/Award | Performance Shares | 2,996 | $0.00 | -- |
| Grant/Award | Stock Appreciation Right | 8,586 | $0.00 | -- |
| Grant/Award | Common Stock | 35.601 | $52.51 | $2K |
Holdings After Transaction:
Restricted Stock Units — 5,993 shares (Direct, null);
Performance Shares — 2,996 shares (Direct, null);
Stock Appreciation Right — 8,586 shares (Direct, null);
Common Stock — 35.601 shares (Direct, null)
Footnotes (1)
- Each RSU represents a contingent right to receive one share of Stepan Company common stock. Vest ratably over three years beginning on the date shown. Each performance share represents a contingent right to receive one share of Stepan Company common stock. The performance shares vest upon the certification of Stepan Company achieving certain performance goals for the performance period ending December 31, 2028. This Form 4/A amends the reporting person's original Form 4 filed on March 4, 2026 (the "Original Filing"). The Original Filing inadvertently reported an incorrect stock appreciation right ("SAR") conversion/exercise price due to an administrative error in the pricing calculation. The correct conversion/exercise price for the reported transaction is $50.06 not $17.47 as previously reported. This amendment corrects the reported conversion/exercise price. No other aspects of the reported transaction are affected.
Key Figures
Stock Appreciation Rights granted: 8,586 rights
SAR exercise price: $50.06 per share
SAR expiration: March 3, 2036
+4 more
7 metrics
Stock Appreciation Rights granted
8,586 rights
Grant dated March 2, 2026, underlying common stock
SAR exercise price
$50.06 per share
Corrected conversion/exercise price for SARs
SAR expiration
March 3, 2036
Expiration date of Stock Appreciation Rights
Performance shares granted
2,996 shares
Contingent on goals for period ending December 31, 2028
Restricted stock units granted
5,993 RSUs
Vest ratably over three years from March 2, 2026
Common stock award
35.601 shares at $52.51
Award dated February 27, 2026, direct ownership
Original SAR price reported
$17.47 per share
Incorrect price in original Form 4, later corrected
Key Terms
Stock Appreciation Right, Restricted Stock Units, performance shares, conversion/exercise price, +1 more
5 terms
Stock Appreciation Right financial
"The Original Filing inadvertently reported an incorrect stock appreciation right ("SAR") conversion/exercise price due to an administrative error"
A stock appreciation right (SAR) is a form of employee pay that gives the holder the right to receive the increase in a company's share price over a set reference price, paid in cash or shares, without having to buy stock first. It matters to investors because SARs can create future cash outflows or dilute existing shareholders if settled in stock, and they align employee incentives with share-price performance like a bonus tied to a home's price rise.
Restricted Stock Units financial
"Each RSU represents a contingent right to receive one share of Stepan Company common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
conversion/exercise price financial
"The correct conversion/exercise price for the reported transaction is $50.06 not $17.47 as previously reported"
Form 4/A regulatory
"This Form 4/A amends the reporting person's original Form 4 filed on March 4, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
FAQ
What insider transactions did STEPAN CO (SCL) report for its CFO?
STEPAN CO reported that CFO Ruben Dario Velasquez received equity-based awards, including stock appreciation rights, performance shares, restricted stock units, and a small common stock grant. All transactions reflect compensation-related acquisitions rather than open-market purchases or sales.
How many Stock Appreciation Rights did the Stepan (SCL) CFO receive?
The CFO received 8,586 Stock Appreciation Rights linked to Stepan common stock. These rights have a conversion or exercise price of $50.06 and expire on March 3, 2036, providing long-term, performance-sensitive compensation tied to the company’s share price.
What correction does this Form 4/A make for Stepan (SCL)?
This amended Form 4 corrects the Stock Appreciation Right conversion or exercise price. The correct price is $50.06 instead of the previously reported $17.47, with all other aspects of the originally reported transaction remaining unchanged.